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Abstract: Diseases such as tuberculosis, hepatitis, and HIV/AIDS are caused by intracellular 
pathogens and are a major burden to the global medical community. Conventional treatments 
for these diseases typically consist of long-term therapy with a combination of drugs, which 
may lead to side effects and contribute to low patient compliance. The pathogens reside within 
intracellular compartments of the cell, which provide additional barriers to effective treatment. 
Therefore, there is a need for improved and more effective therapies for such intracellular 
  diseases. This review will summarize, for the first time, the intracellular compartments in which 
pathogens can reside and discuss how nanomedicine has the potential to improve intracellular 
disease therapy by offering properties such as targeting, sustained drug release, and drug delivery 
to the pathogen’s intracellular location. The characteristics of nanomedicine may prove advanta-
geous in developing improved or alternative therapies for intracellular diseases.
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Introduction
Worldwide, a number of diseases (eg, HIV/AIDS [human immunodeficiency virus/
acquired immune deficiency syndrome], hepatitis, and tuberculosis [TB]) are 
caused by intracellular pathogens. Such diseases can be due to viral,1–8 bacterial,9–16 
fungal,17,18 or other parasitic19–21 infection, as summarized in Table 1. The prevalence 
of each disease may differ geographically, but the intracellular nature of these patho-
gens, which may protect them from a variety of antibiotic therapies and host immune 
responses, presents a treatment challenge for the global medical community. Some 
antibiotic drugs like aminoglycosides and ß-lactams have limited cellular penetration, 
whereas others such as fluoroquinolones or macrolides have the ability to penetrate 
host cells but are poorly retained and therefore inefficient.22 Therapeutic drugs tar-
geting the intracellular pathogens should overcome the cell membrane barriers and 
release and retain the drug intracellularly at the therapeutic level for a desired time 
period. Moreover, multidrug resistance is increasing23–29 and is making intracellular 
disease treatment more challenging. Therefore, there is a need for the development of 
advanced treatment methods to better control intracellular infections. This review will 
summarize the status of intracellular   disease treatments and the current therapeutic 
strategies against common intracellular diseases, and present how nanomedicine 
is emerging as an attractive platform for advanced intracellular drug therapy. Note 
that therapeutic treatments that tune the cell-mediated immune responses against 
intracellular pathogens are important but will not be discussed here.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Intracellular pathogens and current 
treatment approaches
A wide variety of pathogens are capable of causing intracellu-
lar diseases such as HIV/AIDS, hepatitis, and TB (see Table 1). 
In this section, a brief description of selected viral and bacte-
rial diseases is given along with a discussion of the current 
therapeutic strategies against the causative pathogens.
Tuberculosis
TB is a disease caused by Mycobacterium tuberculosis 
(M. tuberculosis). It is estimated that up to 2.2 billion people 
carry latent TB infections worldwide.30 Exposure to TB does 
not necessarily lead to an active infection, as normal human 
immune systems are able to effectively control bacteria, 
and most people remain in a symptom-free latent stage of 
  infection.30 However, susceptible individuals with poor immune 
response or complicating factors such as HIV infection may 
develop an active TB infection.31 People with active infections 
typically experience pain in the chest and a cough with blood or 
sputum (phlegm) lasting more than 3 weeks.32 These symptoms 
could also be accompanied by fatigue, weight loss, fever, chills, 
or night sweats.33 M. tuberculosis is a gram-positive bacterium 
with a very thick cell wall, which is characteristic of the Myco-
bacterium species. The thick cell wall provides an excellent 
permeability barrier, making Mycobacteria resistant to a wide 
variety of antimicrobial agents.23 M. tuberculosis bacteria may 
reside and duplicate within macrophages of the lung.34 A full 
description of M. tuberculosis pathogenesis is beyond the scope 
of this discussion and is reviewed elsewhere.35,36 However, 
an important factor is the bacteria’s ability to avoid the cell-
mediated immune response through granuloma formation,10 
such that treatment of TB remains a challenge.
At present, the treatment of choice for an active TB 
  infection is long-term antibiotic therapy, with an initial 
“intensive phase” consisting of the four first-line anti-TB 
drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) 
followed by a typical 4 month course of rifampicin and iso-
niazid alone.37 This has been the most effective treatment to 
date, although, due to the length of antibiotic therapy, side 
effects frequently develop38 and the cost is high.39 These 
factors may lead to low patient compliance and contribute 
to the development of drug-resistant bacteria.40
HIv
Infection with HIV is a significant ongoing problem   worldwide. 
As HIV infection progresses, infected individuals develop AIDS. 
According to the latest statistics from the World Health Organi-
zation, there are 33.3 million people living with HIV/AIDS.41 
Many of those infected live in sub-Saharan Africa, where 
access to treatment is extremely costly or unavailable. There 
have been major developments in the treatment of HIV/AIDS 
since the approval of zidovudine (Retrovir®; GlaxoSmithKline, 
Durham, NC) in 1987.8 Current therapeutic efforts consist of a 
combination of several drugs,42 typically from different classes 
of antiviral drugs.43,44 This regimen is referred to as highly active 
antiretroviral therapy (HAART) and has become the standard 
of care for those infected with HIV . There are five classes of 
drugs   available for HIV/AIDS   treatment, including nucleoside 
Table 1 Summary of disease-causing intracellular pathogens
Associated disease(s) References
Viral pathogens
Herpes simplex Type 1: oral herpes (cold sore, fever blister) or  
Type 2: genital herpes (warts, ulcers)
1,2
Hepatitis C Liver cirrhosis, hepatocellular carcinoma (HCC) 3,4
Respiratory syncytial virus Pediatric viral respiratory disease 5,6
Human immunodeficiency virus Acquired immunodeficiency syndrome (AIDS) 7,8
Bacterial pathogens
Mycobacterium tuberculosis Tuberculosis 9,10
Salmonella enterica serovars Typhi, Paratyphi Typhoid fever 11,12
Brucella species B. melitensis, B. abortus, B. suis Malta fever or undulant fever 13–15
Listeria monocytogenes Listeriosis, meningitis in newborn babies 16
Fungal pathogens
Candidia albicans Multiple cutaneous and mucosal forms; frequently
encountered oral form is thrush
17
Aspergillus fumigatus Pulmonary aspergillosis 18
Other pathogens
Leishmania (parasite) Cutaneous or tegumentary leishmaniasis 19,20
Plasmodium species (protist) P. vivax, P. ovale,
P. malariae, P. falciparum, P. knowlesi.
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reverse transcriptase inhibitors,   nucleotide reverse transcriptase 
inhibitors, non-nuceloside reverse transcriptase inhibitors, 
protease inhibitors, and viral fusion and integrase inhibitors. 
Typical regimens are combinations of three or four drugs, with 
subsequent modifications made based on the patient’s response 
to therapy.45 Changes made to a patient’s regimen are often based 
on drug resistance testing, and take into consideration toxic-
ity and tolerability of the new treatment strategy.45 Although 
HAART has increased the median survival time of HIV/AIDS 
patients from less than a year to about 10 years,29 patients often 
develop multidrug-resistant strains of the virus41 over the course 
of therapy, leading to poor treatment outcomes.46
Hepatitis C virus
It is estimated that at least 3 percent of the world’s population 
is infected with the hepatitis C virus (HCV).3,47 The virus 
affects only humans and is considered a “silent” disease, 
as infected individuals are usually symptom free until later 
stages of infection when liver inflammation48 occurs. HCV 
can cause liver scarring and cirrhosis, which ultimately 
leads to hepatocarcinoma (liver cancer) and death.3,48 
  Unfortunately, there is no effective vaccine49 against HCV , 
and the “gold standard” of HCV treatment is combination 
antiviral therapy with ribavirin and interferon-α;4 however, 
both of these compounds are highly toxic and may cause 
severe side effects. Several months of treatment are   usually 
required to eradicate a chronic infection, and the cost of 
therapy is high.49 These factors contribute to low patient 
compliance, making therapy less effective and potentially 
contributing to the development of viral resistance.29
Typhoid fever
Typhoid fever is an acute illness caused by the bacterium 
Salmonella enterica serovar Typhi (S. Typhi) or   Paratyphi, 
which causes about 20 million cases of illness per year.50 These 
bacteria are usually ingested by consuming contaminated 
food or water.51 Once ingested, the bacteria translocate across 
intestinal epithelial cells and establish an intracellular growth 
environment within macrophages.52 The bacteria survive within 
Salmonella-containing vacuoles in infected macrophages 
and later spread to organs such as the liver and spleen.11,12,53 
Infected individuals often experience sustained high fevers (up 
to 103°F), stomach pains, headache,   weakness, and appetite 
loss.51 Several vaccines against S. Typhi have been developed,54 
although they provide only short-term protection against the 
disease due to failure of the immune system to build a lasting 
response.50,54 Typhoid fever is endemic in many developing 
countries,55 where access to vaccines and antibiotic drugs is 
limited and expensive even if available. Standard treatment for 
S. Typhi infection is the antibiotic chloramphenicol, although 
resistance has been reported.50 Newer antibiotics like the fluoro-
quinolones have also proven effective in treating typhoid fever, 
but the widespread use of these drugs for a range of febrile 
illnesses in developing countries is contributing to the develop-
ment of more drug-resistant strains of the bacterium.55
Major challenges in treating 
intracellular pathogens
Tables 2A and B summarize the common intracellular viruses 
and bacteria and their related current therapeutic approaches. 
One can see that intracellular treatment approaches gener-
ally involve long-term therapy with a combination of drugs. 
Side effects can develop due to the drug’s inherent toxicity 
or the length of drug exposure. One of the critical challenges 
in treating these types of infections is to get enough drugs to 
reach the pathogens within their intracellular compartments. 
After reviewing the literature, we found evidence that intra-
cellular pathogens reside in phagosomes,15,34,56 vacuoles,52,53 
cytosol,16,57,58 and nucleus,1,59,60 and may interact with the 
Golgi apparatus61 and endoplasmic reticulum62–66 of host cells 
 ( Figure 1). The host cell membranes make it a challenge for 
many drugs to reach the invading pathogens. Moreover, some 
antiviral and antibiotic medications have short half-lives, 
requiring frequent and large doses to obtain a therapeutic 
effect, which may lead to high cost, low patient compliance, 
and severe side effects. In addition, drug resistance may be 
developed when patients do not fully comply with their treat-
ment regimens28 or when pathogens are exposed to drugs at 
suboptimal concentrations67 for an extended time period. An 
alerting new phenomenon is that some pathogens that have 
traditionally been considered extracellular are emerging as 
intracellular pathogens and may lead to new types of intracellu-
lar diseases. As an example, Staphylococcus aureus (S. aureus) 
has long been considered an extracellular pathogen, although 
recent evidence in the literature demonstrates that this bacte-
rium is capable of being internalized and of surviving within 
host cells (eg, osteoblasts68–72), and may contribute to recurrent 
infections.73 In order to reduce side effects, improve patient 
compliance, and reduce the development of drug resistance, 
more effective therapeutic approaches need to be developed.
An ideal drug treatment method to eradicate intracellular 
pathogens is one that has the following characteristics: the 
ability to penetrate host cells and reach the pathogens, high 
efficacy and low toxicity, and sustained and site-specific 
drug release.22 Recent evidence from the literature shows that 
nanomedicine is emerging as a promising potential treatment International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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for intracellular pathogens, as nanomedicine has the capacity 
to address these specific challenges.
Nanomedicine as an emerging 
therapeutic approach
Conventional therapies for the treatment of intracellular 
  diseases have existed for many years. These treatments 
may be further improved as we enter a new era of therapies 
based on nanomedicine. Nanomedicine can be most suc-
cinctly defined as “the application of nanotechnology to 
medicine.”74 There are many potential advantages of using 
nanomedicine over the conventional therapies previously 
described.   Combining new knowledge of nanomaterials with 
our current understanding of cellular and molecular func-
tions may allow for the development of novel and advanced 
nanomedicines. As discussed here, nanomedicine has the 
capacity to incorporate, encapsulate, or conjugate a variety of 
drugs in order to target specific cell populations and to offer 
tunable and site-specific drug release. Nanomedicine could 
be advantageous in treating intracellular diseases.
Biocompatibility and nanotoxicity
Biocompatibility is an important feature of any drug delivery 
system, and the goal is to minimize nonspecific cytotoxic 
effects to healthy tissues while maximizing drug effects at the 
target tissue or against invasive pathogens.75 Nanoparticles 
have been fabricated using a variety of materials, including 
poly(lactide-co-glycolide) (PLGA);76–81 poly-lactic acid 
(PLA);77,82,83 polymethacrylic acid (PMA);84,85 polyethylene 
glycol (PEG);77,86,87 “natural” polymers such as chitosan,88,89 
gelatin,90,91 or alginate;92,93 and other materials such as 
lipids,94–96 gold,75,97 and silica.98–101
PLGA has been approved by the Food and Drug Adminis-
tration for several biomedical applications, including surgical 
sutures, implants, and prosthetic devices.78 PLGA micro- or 
nanoparticles have also been used for a variety of drug deliv-
ery applications.79 PLGA displays good biocompatibility, bio-
degradability, suitable degradation kinetics, and mechanical 
properties and is easy to process. For this   reason, PLGA is 
an attractive candidate for nanoparticle-based drug delivery 
systems, and there is a large body of ongoing research in this 
area. Other polymers such as PLA, PMA, PEG, chitosan, gela-
tin, and alginate also show promise as drug delivery vehicles 
due to their biocompatible properties. PEG may be used as a 
“coating” to prevent the rapid removal of   nanoparticles from 
the bloodstream by the mononuclear phagocytic system, 
which may increase nanoparticle circulation time and theoreti-International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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cally improve the therapeutic capacity of the nanoparticle.83,86 
Chitosan and alginate are polymers derived from natural 
sources and may offer more “friendly” conditions for the 
encapsulation or incorporation of DNA or peptides, because 
the use of organic solvents can be avoided.93
Lipids are also being explored as potential nanodelivery 
systems, either as liposomes or lipid nanocapsules (LNCs). 
Liposomes are composed of lipid bilayers surrounding 
a hydrophilic “core” and can be designed to incorporate 
hydrophobic drugs within the lipid bilayer or hydrophilic 
drugs within the aqueous core.94 Liposome-encapsulated 
aminoglycosides (such as gentamicin) have shown higher 
therapeutic efficacy than conventional aminoglycoside prepa-
rations in the liver and spleen using a murine S. typhi infection 
model.94 Amphotericin B (an antifungal) has also been encap-
sulated in lipids and administered to mice with an Aspergillus 
fumigatus infection.95 Liposome-treated mice have survived 
longer than mice treated with other amphotericin B prepara-
tions, with reduced renal toxicity and a prolonged drug circu-
lation time.95 These liposome formulations could be a better 
treatment for diseases affecting the liver or spleen (eg, typhoid 
fever, hepatitis). LNCs are another type of lipid-mediated 
delivery system under exploration. LNCs are considered a 
“hybrid” between a polymer nanoparticle and a liposome, 
with an oily core surrounded by a membrane composed 
of PEGylated surfactants.96 LNCs have shown promise 
in in vitro and some animal models encapsulating anticancer 
drugs such as paclitaxel, doxorubicin, and etoposide.96 
The results of these studies have indicated higher intracellular 
drug delivery and reduced tumor size in vivo when LNC 
formulations were administered.
In contrast to these “soft” polymer-based nanoparticle sys-
tems, metals such as gold have also been explored as potential 
drug delivery vectors. Gold is an attractive drug delivery vector 
due to the ease with which biomolecules such as protein or 
DNA can be attached to the gold surface using thiol chemistry.75 
This process can also allow attachment of multiple targeting 
or functional groups to the nanoparticle surface to produce a 
multifunctional nanoparticle. Although gold nanoparticles can 
be easily functionalized, these nanoparticles may accumulate 
in tissues over time because they are not biodegradable. The 
effects of long-term nanoparticle accumulation are unknown, 
so in many cases it may be better to use a material that is fully 
biodegradable. Silica-based compounds are another option, 
as the biodegradation of silica avoids tissue accumulation 
concerns,98 and it has been demonstrated that a variety of 
agents have been successfully incorporated into silica-based 
nanoparticles99–101 for drug delivery applications.
Although each of these materials offers its own set of 
characteristics and biocompatible properties, some materi-
als may be more suited to certain applications than others. 
It is important to determine the desired properties of the 
nanomedicine for defined applications.
Cellular penetration and intracellular 
delivery
One critical challenge in treating intracellular pathogens is to 
get enough drugs to reach the pathogen within an intracellular 
Nuclear membrane
Mitochondrion
Nucleolus
Ribosomes
(1) Cytoplasm
Centrioles
Cell membrane
(3) Nucleus
(4) Golgi apparatus
(5) Endoplasmic reticulum
(2) Phagosome/lysosome
or vacuole
Figure 1 Potential locations of intracellular pathogens. In a typical eukaryotic cell, pathogens may be internalized via endocytic mechanisms before establishing their 
intracellular life cycle. Pathogens may reside in various locations, including the cytosol, phagosome, lysosome, or vacuole compartments and the nucleus, and some may 
associate with the Golgi apparatus or endoplasmic reticulum. (1) Cytosol (Francisella tularensis,57 Listeria monocytogenes,58 Shigella64). (2) Phagosome/lysosome or vacuole 
(Mycobacterium tuberculosis,43,45 Brucella species,15 Salmonella,52,53 Legionella56). (3) Nucleus (herpes simplex virus,1,60 HIv59). (4) Golgi apparatus (Chlamydia61). (5) endoplasmic 
reticulum (hepatitis C virus,65 Brucella,63 Toxoplasma gondii,66 Legionella pneumophilia62,64). 
Note: Reproduced with permission from the Scripps Institution of Oceanography, UCSD.
Abbreviations: HIv, human immunodeficiency virus; UCSD, University of California, San Diego.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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compartment. Nanoparticles can be internalized by endocytic 
mechanisms, which include receptor-mediated or clathrin-
coated pit endocytosis.102 Nanoparticles may reside within 
acidic endolysosome compartments following endocytosis,79 
and premature drug release within this acidic compartment 
may cause drug degradation and render treatment ineffective. 
It is therefore important for the nanoparticle to escape this 
compartment and gain access to the cytosol where either the 
drug cargo may be directly released or the nanoparticle goes 
on to further target a specific organelle. For instance, PLGA 
nanoparticles carrying doxorubicin are reportedly capable 
of escaping the endolysosomal compartment by a reversal 
of their surface charge. This allows the particles to interact 
with the membrane and escape into the cytosol where the 
doxorubicin is released.79
There are a number of sources that report time- and 
concentration-dependent uptake of nanoparticles by a vari-
ety of cell types such as smooth muscle cells,79 endothelial 
cells,103,104 macrophages,40,105–107 and tumor cells.108–113 The 
uptake of PLGA nanoparticles containing bovine serum albu-
min as a model drug was found to be concentration dependent 
in human vascular endothelial cells, approaching first-order 
kinetics.103 An in vitro uptake and cellular trafficking study 
using mesoporous hybrid silica nanoparticles demonstrated 
that the particles were internalized by receptor-mediated 
endocytosis, were localized in the endocytic compartment, 
and then released their cargo within the cytosol.100 Another 
in vitro study examined the uptake of drug-loaded thiolated 
PMA hydrogel capsules.113 The tracking experiments revealed 
that nanocapsules were taken up by endocytic mechanisms 
in a time-dependent manner and the drug was released 
throughout the cell. Collectively, these studies demonstrate 
that nanoparticles are capable of cellular penetration and 
intracellular drug release. This is an important characteristic 
of a nanomedicine that targets intracellular pathogens and 
promotes direct killing, as the drug must be able to effec-
tively reach the invading pathogens within the intracellular 
compartment.
Targeting to specific cell types
The goal of targeting nanomedicines to specific cell popula-
tions is to increase the therapeutic efficacy of the drug while 
minimizing damage to healthy cells and tissues, thereby reduc-
ing the incidence and severity of side effects. Currently, the 
majority of experiments demonstrating the targeting of nano-
particles are related to cancer/tumor targeting, although these 
same concepts can be applied to pathogen-infected cells and 
the intracellular compartments98 where the pathogens reside. 
Nanoparticles can be targeted toward specific cell populations 
by conjugating targeting ligands to the surface of the nano-
particles. These targeting ligands can be attached directly to 
nanoparticle surfaces or via a spacer (eg, PEG), which acts to 
enhance the flexibility of the targeting ligand and increase 
the likelihood that it will bind the appropriate receptor on 
the target cell.110,114 There are a variety of methods available 
to attach ligands to nanoparticle surfaces.115,116 Targeting 
ligands can include antibodies (whole or fragment), recep-
tors or receptor ligands, peptides, aptamers, or other small 
molecules.114 A few examples are presented here.
When incorporating antibodies on nanoparticle surfaces, 
it is important to consider whether attachment will affect 
the binding site or structure of the antibody. Hybrid lipid 
nanoparticles composed of PLGA, phospholipids, and an 
outer PEG layer have shown targeting capacity to pancreatic 
cancer cells when coupled with an anticarcinoembryonic 
antigen (CEA) half-antibody.112 Nanoparticles incubated with 
CEA-presenting pancreatic cancer cells showed selective 
uptake of targeted nanoparticles over nontargeted control 
nanoparticles.
Receptor ligands can also act as targeting moieties. 
It has recently been reported that nanosized poly(ethylene 
glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles 
bearing a surface epidermal growth factor (EGF) have been 
targeted to breast cancer cells overexpressing the epidermal 
growth factor receptor (EGFR) in vitro and in vivo.108 The 
uptake of the nanomicelles was two-fold higher using EGFR-
  overexpressing cells compared with cells that express low 
levels of EGFR. These results were confirmed using a xeno-
graft mouse model, with mice bearing EGFR-overexpressing 
tumors demonstrating increased tumor uptake of the particles 
compared with mice bearing low EGFR-expressing tumors.
Polyester nanoparticles carrying paclitaxel can be targeted 
to irradiated tumor cells with a short peptide, Gly-Ile-Arg-
Leu-Arg-Gly (GIRLRG), which binds specifically to GRP78 
receptors expressed by glioma and breast tumor cells in 
response to radiation therapy.109 In vitro and in vivo studies 
were used to compare tumor volumes following treatment 
with control and targeted nanoparticles. Mice treated with 
nanoparticles bearing the targeting component had a signifi-
cant decrease in tumor volume compared with control.
Conjugation of an A10 aptamer to PLGA/PEG nanoparti-
cles has also been shown to be an effective targeting strategy.116 
The A10 aptamer binds to the prostate-specific membrane 
antigen (PSMA) on the surface of prostate cancer cells, and the 
A10 aptamer-conjugated nanoparticles showed higher uptake 
by PSMA-positive cells than by PSMA-negative cells.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Site-specific and tunable drug release
In order to effectively eradicate intracellular pathogens, 
drugs that are intended to kill the pathogens directly 
should reach the intracellular locations of infected host 
cells. As we have summarized in Figure 1, locations may 
include phagosomes,15,34,56 vacuoles,52,53 cytosol,16,57,58 and 
nucleus1,59,60 and may interact with the Golgi apparatus61 or 
endoplasmic reticulum.62–66 With proper engineering and 
design, nanoparticles can be tailored to carry their drug pay-
loads into the infected cells and then release the drug within 
specific intracellular compartments. One way to accomplish 
site-specific drug release is to use pH-responsive polymers. In 
one study, short peptides were conjugated to pH-responsive 
polymers designed specifically to disrupt the endosomal 
membrane at pH 5.5 and subsequently release the peptide 
into the cytosol.117 The polymers had no membrane-disruptive 
activity at pH 7.4 due to a “masking” PEG group, which is 
later cleaved to expose the membrane-disruption domain at 
pH 5.5. Peptide-polymer conjugates demonstrated a diffuse 
cytosolic distribution after 1 hour, the time normally required 
for macrophage endosomes to mature into lysosomes. Uncon-
jugated peptide was located primarily in the lysosome after 
the same time period, indicating that the peptide itself was 
unable to escape into the cytosol. This polymer technology 
may allow for local drug delivery to the cytosol, although it 
is more critical to reach the specific intracellular location of 
the pathogen, such as a vacuole or the nucleus.
It has been demonstrated that nanoparticles can be 
  specifically targeted to mitochondria118 or nucleus119 and 
may be capable of entering vacuoles120 where pathogens 
such as Salmonella may reside during an infection process. 
Although intracellular pathogens do not typically live within 
mitochondria, pathogens such as Listeria monocytogenes 
can secrete toxins that interfere with normal mitochondrial 
function.121 So the ability to target mitochondria may provide 
a means to treat these types of infection and attenuate the 
effects of secreted toxins. One study successfully localized 
fluorescent nanodiamonds conjugated with mitochondrial 
protein antibodies to mitochondria in live cells.118 The inher-
ent fluorescence of these nanodiamonds allowed for tracking 
the localization of the nanoparticles, and the microscopy 
experiments revealed that these nanodiamonds were capable 
of specifically binding the mitochondria compared with 
control nanodiamonds without conjugated antibody.
Nuclear targeting has been demonstrated in a similar 
manner by conjugating nuclear localization signal (NLS) 
peptides on the surface of PLGA nanoparticles for the nuclear 
delivery of doxorubicin to cancer cells.119 The NLS-targeted 
  nanoparticles demonstrated a six-fold increase in uptake 
compared with free doxorubicin in solution, and also a 
2.5-fold increase in uptake over nontargeted nanoparticles. 
Cells treated with NLS-targeted nanoparticles also showed 
a higher toxicity than control nanoparticles, which was 
expected due to the increased delivery of drug to its nuclear 
target site. Nuclear targeting would be especially useful in 
viral infections such as HIV and HSV , as these viruses must 
enter the nucleus to begin their replicative life cycles.
There is also evidence that demonstrates that   nanoparticles 
loaded with ampicillin are capable of entering cells and 
delivering the drug within Salmonella-containing vacuoles 
(SCVs).120 Ampicillin was tritium-labeled and found to 
  localize within both the cytosol and SCVs using ultrastruc-
tural autoradiography. The colocalization of the drug with 
the bacteria led to enhanced bacterial killing and   elimination 
compared with control cells treated with ampicillin in 
  solution. The colocalization of the drug within the SCVs 
is an important step in effectively targeting intracellular 
pathogen compartments.
Another issue plaguing intracellular pathogen treatments 
is the lower concentration of drug at the target site and the 
short duration of efficacy of the drug administered. Large 
and frequent doses of the drugs are often required to obtain 
a therapeutic effect. Nanoparticles have the potential to 
overcome this issue by offering sustained release of drugs, 
which would lower the required dose and decrease the fre-
quency of administration.122 As an example, polymer-based 
nanoparticles composed of PLGA are able to sustain release 
of a variety of drugs, such as rolipram for 7 days,123 gen-
tamicin for 25 days,124,125 and dexamethasone for 15 days.126 
  Hyperbranched poly(amine-ester)-PLGA nanoparticles have 
also demonstrated sustained release of isoniazid, an important 
anti-TB drug, up to 14 days.81 Another study targeted gelatin 
nanoparticles loaded with rifampicin, another anti-TB drug, 
to macrophages.91 Test results indicated that the rifampicin-
loaded gelatin nanoparticles were capable of localizing in the 
lungs and reducing bacterial loads in a mouse model of TB. 
In addition, nanoparticle treatment was as effective as tra-
ditional daily oral rifampicin at a reduced dosing frequency 
(every 3 days), due to the sustained release of rifampicin 
from the gelatin matrix.91
Perspectives for the future
We have reviewed the current therapeutic strategies against 
commonly encountered intracellular pathogens like viruses 
and bacteria, and have evaluated the potential of nanomedi-
cine to improve upon the current treatments. When treating International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3289
Nanomedicine for intracellular diseases
intracellular diseases, it is important to avoid or prevent 
further development of pathogen resistance, which is becom-
ing a major problem for the management of TB.23 Generally 
speaking, the success of an antibiotic drug relies on its ability 
to penetrate the bacterial cell wall and membranes and to 
bind to its target site (eg, protein, enzyme).127 Bacteria may 
develop resistance by mutating various drug target sites,27 
and viruses may also develop drug resistance through genetic 
mutation and recombination events29 that can render our cur-
rent treatments ineffective. For this reason, there is a need for 
new drugs with novel mechanisms of action that may slow 
or stop the development of pathogen resistance.
As an example, recent literature has emerged touting the 
potential of cationic antimicrobial peptides (CAMPs) to serve 
as an alternative to conventional antibiotic therapy.128–132 
Antimicrobial peptides are short, positively charged peptides 
that are produced endogenously by human epithelial tissues 
where they function to prevent invasion of pathogens, dem-
onstrating broad-spectrum killing activity against bacteria, 
yeast, and fungi.129,133 The complete mechanism of CAMP 
action is yet to be fully understood, but one proposed mecha-
nism suggests that the CAMPs interact electrostatically with 
the negatively charged molecules on the outer surface of 
bacteria, where they can insert themselves into the membrane 
and form a pore.129 Such a disruption in the bacterial cell 
wall and membranes will affect the osmolytic balance of the 
bacterium and ultimately cause cell death. Because CAMPs 
do not have a specific molecular target per se, pathogens 
may have more difficulty in developing resistance to these 
peptides. There is also some evidence indicating that CAMPs 
can help modulate exogenous antibiotic action against sev-
eral strains of S. aureus.134 Bacterial cultures treated with 
both CAMPs and antibiotics had lower antibiotic minimum 
inhibitory concentration values than for cultures treated with 
antibiotics alone, indicating complementary action between 
the CAMPs and antibiotics.
As a result, these CAMPs are attractive targets for the 
development of novel nanomedicines to treat intracellular 
diseases. It may be possible to design nanoparticles capable 
of carrying CAMPs into the cell, or to develop self-assembled 
CAMP nanoparticles. The development of such nanoparticles 
may greatly improve intracellular drug therapy by offering high 
efficacy against a variety of pathogens, and also offer very 
high biocompatibility, as endogenous CAMPs can be used. 
We anticipate that CAMP nanoparticles will be a potential 
advanced nanomedicine for intracellular disease treatments.
Another potential strategy to improve intracellular 
disease treatments is to take advantage of the preferential 
  accumulation of nanoparticles by the reticuloendothelial 
system (RES). The RES can also be referred to as the “mono-
nuclear phagocytic system” and is composed of macrophages 
residing in the liver, spleen, and lungs. Normally, this phe-
nomenon is avoided in nanomedicine, as the RES removes the 
nanoparticles from circulation and may prevent drugs from 
reaching target   tissues. However, this treatment modality may 
be particularly useful in treating intracellular diseases such as 
TB (affecting the lungs) or typhoid fever (affecting the liver 
and spleen), as these pathogens primarily live and duplicate 
within macrophages of the affected organs. Using nanopar-
ticles to deliver drugs of interest to fight these diseases may 
be aided by the natural tendency of these cells to internalize 
nanoparticles, which would help reduce unnecessary tissue 
exposure and likely decrease the amount of drug required, 
because it is being delivered to the appropriate cell.
To create the “perfect” intracellular drug delivery system 
for fighting infections, certain characteristics of nanoparticles 
or nanomedicine must be successfully incorporated such 
that the medicine exhibits acceptable biocompatibility, pos-
sesses targeting capacity, and offers efficient and sustained 
drug release at the target site. Figure 2 illustrates an “ideal” 
nanoparticle drug delivery system with such characteristics 
suited to treat intracellular diseases. The nanomaterial used 
will vary with each application, but there are a variety of 
biocompatible materials available, as summarized in Table 3. 
The drug may be used to form the nanoparticle, encapsulated 
within a polymer matrix, or attached to the surface of a solid 
“carrier” nanoparticle. The incorporation of surface target-
ing components to help localize to the affected tissue may 
improve therapeutic efficacy, along with the presence of mol-
ecules to enhance cellular penetration such as cell-penetrating 
Cell-penetrating
peptide
PEG linker
Polymer matrix, drug,
imaging agent, etc
Targeting moiety
(antibody, aptamer,
receptor ligand, etc)
Figure 2 Components of an “ideal” nanoparticle for intracellular drug delivery. 
The important components of a nanoparticle used for intracellular drug delivery 
include  choice  of  nanomaterials  (eg,  polymer,  gold),  targeting  molecules,  cell-
penetrating  peptides  (to  promote  internalization),  and  the  incorporated  drug 
molecules of interest. 
Abbreviation: PeG, polyethylene glycol.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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peptides (CPPs). CPPs are short, cationic peptides, typically 
derived from the HIV TAT proteins,135 which have been 
shown to readily translocate through cell membranes. The 
addition of CPPs, such as TAT, to the surface of a nanopar-
ticle can increase the efficiency with which the nanoparticles 
are delivered intracellularly,136,137 although the mechanism by 
which these CPPs are able to enter cells is currently under 
debate. It is suggested that either the CPPs promote direct 
translocation through the membrane via electrostatic interac-
tions or the CPPs bind to specific receptors on the membrane 
and induce rapid receptor-mediated endocytosis.137 In either 
case, promoting efficient cellular penetration is critical for 
the treatment of intracellular diseases.
Nanomedicine meets the requirements for an “ideal” drug 
delivery system to improve intracellular disease therapy; 
however, we are still exploring this relatively new field. 
It is early to assess how quickly nanomedicine will be adopted 
and integrated into mainstream health care. Research on 
nanomedicine is relatively well funded,138 so it is likely that 
many new treatment methods will be approved and avail-
able in the future. However, this investment cost for drug 
development is still high from an economic standpoint,139 
and the price will probably be passed down to patients via 
high prescription copays and may not be available for years 
in developing areas where these improved therapies are 
needed most. Initially, this may be a deterrent to promoting 
nanomedicine, but over the long term with new cost-effective 
technologies, higher drug efficacy, and better treatment out-
comes, the price will become acceptable.
Conclusion
The burden of treating intracellular diseases is continually 
increasing due to the sheer number of people living with dis-
eases such as HIV/AIDS, hepatitis, and TB worldwide, along 
with the increasing incidence of drug resistance. We have 
summarized the locations where these pathogens reside, such 
as phagosomes,15,33,55 vacuoles,51,52 cytosol,16,56,57 nucleus,1,58,59 
Golgi apparatus,60 and endoplasmic reticulum.61–65 The major 
challenges in treating these invasive pathogens include get-
ting enough drugs to penetrate the host cell and reach the 
pathogen, having high drug efficacy and low toxicity, and 
maintaining sustained, site-specific drug release throughout 
the duration of treatment. In the future, it may be possible 
to improve disease treatment by utilizing the uptake of 
nanoparticles by the RES, especially in the case of TB and 
hepatitis, which affect macrophages. Additionally, looking 
to endogenous sources such as CAMPs or other immuno-
modulatory compounds such as interleukins (not covered) 
may further improve upon current therapies.
The literature presented here shows the potential for 
nanomedicine to address these challenges and improve 
upon the current therapeutic strategies. The incorporation 
of nanomedicine into mainstream health care is a lofty, but 
achievable, goal. Researchers from multiple disciplines must 
work together, push the boundaries of science at the nano-
scale, and incorporate concepts from biology, engineering, 
and drug design in order to make this goal a reality.
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